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Background: Glioblastoma, the most frequent and malignant adult brain tumor, has been extensively 
studied. However, there is no effective treatment, and to overcome this challenging scenario, it is essential to 
improve preclinical biological models. This study aimed to molecularly characterize short-term glioblastoma 
primary cultures and to compare them with patient tumor profiles. 
Methods: Glioblastoma cell lines were established from Barretos Cancer Hospital patients diagnosed with 
glioblastoma. The cells were cultured with DMEM +10% FBS +1% PS and were molecularly characterized 
using array CGH (aCGH), next-generation and Sanger sequencing. 
Results: We established four short-term glioblastoma cultures and we found that the primary cells 
exhibited a diversity of chromosomal aberrations, with gain of chromosome 7 and loss of chromosomes 10, 
13 and 17p being the most frequent alterations. Mutation profiling showed that hotspot TERT promoter 
mutations were present in 3/4 cases, followed by mutations in TP53 (2/4) and in the RB1, BRAF and PTEN 
(1/4) genes. A similar chromosomal and mutation pattern was observed in all short-term cultures and 
matched frozen tumors. 
Conclusions: Herein, short-term glioblastoma primary cultures were successfully characterized and had 
genetic make-ups that were similar to those of patient tumors, suggesting that short-term primary cultures 
are suitable in vitro models for studies of glioblastoma biology.
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Introduction
Central nervous system (CNS) tumors account for 
approximately 2% of all adult malignancies worldwide and 
represent the most prevalent cancer among those 0–19 years 
old (1,2). The SEER (Surveillance, Epidemiology, and End 
Results Program) cancer database recorded an incidence of 
6.4 per 10,000 persons per year and 4.3 per 10,000 persons 
per year during 2008–2012 in the United States (3). In Brazil, 
there are expected to be 5,540 new cases of CNS tumors in 
men and 4,830 in women in 2016, making them the eleventh 
most frequent tumor type, considering both genders (4). 
Among the malignant CNS tumors, gliomas are the most 
frequent and are divided into four WHO malignancy 
grades (5). Glioblastoma (WHO grade IV) is not only 
the most aggressive but is also the most frequent subtype, 
representing more than 50% of all adult gliomas (2,5-7). 
Clinically, these tumors can be subdivided into primary 
or de novo glioblastoma, which appears in older patients 
(~65 y) and without clinical or histopathological evidence 
of a preexisting lesion, or secondary glioblastoma, arising 
in young adult patients (~45 y) from lower grade lesions, 
such as diffuse astrocytoma (WHO grade II) or anaplastic 
astrocytoma (WHO grade III) (5,8-10). Histologically, 
glioblastomas are characterized by high cellularity, 
diffuse infiltration, intense mitotic activity, microvascular 
proliferation, nuclear atypia, cellular pleomorphism, 
necrosis and a high intertumoral and intratumoral 
morphological heterogeneity, which demonstrate the high 
genomic instability of these tumors (5,10,11). Glioblastoma 
is one of the most devastating human diseases, with a 
mean survival of 12 to 15 months (5,12-14). Currently, the 
standard treatment consists in the widest possible resection 
followed by a combined regimen of radiation therapy and 
adjuvant temozolomide-based chemotherapy (15,16). 
In the last decade, recurrent genomic aberrations of 
glioblastomas have been elucidated, and it is now clear 
that several molecular pathways distinguish adult from 
pediatric cases and primary from secondary glioblastomas, 
and recently, 5 molecular subclasses (proneural G-CIMP, 
proneural non G-CIMP, neural, classical and mesenchymal) 
were reported in adult glioblastomas (10,13,17-19). 
According to The Cancer Genome Atlas (TCGA), the 
tumor suppressor genes PTEN and TP53 are among the 
most frequently mutated genes, especially among newly 
diagnosed adult patients (14,17). The integrated analysis 
of the complex chromosomal and genetic aberrations 
present in glioblastomas shows an interaction between 
three major signaling pathways: the receptor tyrosine kinase 
receptors (RTKs), the p53 and RB (14,17). In fact, 74% of 
glioblastomas harbor somatic alterations of these pathways, 
suggesting that their deregulation is extremely important 
for tumor development (14,17). An analysis by the TCGA 
consortium confirmed that losses are more frequent than 
amplifications in GBM (17,20). Brennan et al. analyzed 
the DNA copy-number alterations of 543 glioblastomas 
and showed that the amplifications and copy number gains 
are more frequent on chromosomes 7 (7p11.2, 7q31.2 
and 7q21.2), 12 (12q14.1 and 12q15) and 4 (4q12), and 
the main deletions occur on chromosomes 10 (10q23.31), 
13 (13q14.2 and 13q21.2), 22 (22q13.31) and 9 (9p21.3) 
(17,21). In addition, mutations in the IDH1/2, PDGFRA 
and NF1 genes have been associated with the development 
of glioblastoma (22). Notably, several recent studies report 
a high frequency (50–83%) of mutations in the promoter 
region of the TERT gene, constituting one of the most 
common somatic events in adult glioblastomas currently 
observed (23-25). 
Despite these major advances in the understanding of the 
genomics of glioblastoma, there has been little progress in 
developing therapeutic applications, so the clinical impact 
has been limited. For this reason, it is essential to develop 
model systems that better mimic the genomic diversity 
of individual tumors and use these systems for preclinical 
research designed to develop better treatment options (26). 
One of these models is the development of short-term 
primary cell cultures from patient tumors, which has 
become more popular in recent years and has the practical 
advantage of providing an unrestricted source of material 
for tumor biology and for the characterization and testing 
of new drugs (26,27).
In the present study, we aimed to determine the 
molecular profile of short-term glioblastoma primary 
cultures using array-CGH (aCGH), next-generation 
sequencing (Ion Torrent) and Sanger sequencing for 
confirmations and extended the analysis to the TERT 
promoter gene. We also compared the molecular profiles 
of the short-term primary cultures with the corresponding 
frozen tumor tissues. 
Methods
Samples
Four short-term tumor primary cultures were established 
from patients diagnosed with glioblastoma (WHO grade 
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IV) at Barretos Cancer Hospital, Barretos, São Paulo, 
Brazil. The clinico-pathological characteristics, such as 
tumor localization, resection, treatment, KPS (Karnofsky 
Performance Status) and patient status, were collected 
from medical records. The resected tumor was divided into 
three portions. The first portion was sent to the Pathology 
department for a confirmatory diagnosis, the second piece 
was frozen and stored at a hospital biobank, and the last 
portion was used for primary cell culture establishment. 
All of the patients recruited in the study gave informed 
consent, and the experimental protocols were approved 
by the Barretos Cancer Hospital local Ethics Committee 
(491/2011). 
Establishment of short-term primary cell cultures 
The primary cultures were established from resected 
glioblastomas, which were pre-operatively detected by 
magnetic resonance imaging (MRI). In the operating 
room, the excised tumor tissue was immediately placed 
in 1X PBS (Phosphate Buffer Solution-Sigma-Aldrich) 
and was sent to the laboratory to be processed as previous 
described by Martinho et al. (28), within a period that 
ranged from 30 minutes (RT, room temperature) to a 
maximum of 24 hours (4 ℃). Briefly, the fresh tumor 
tissues were washed in 1X PBS to remove the remaining 
blood and debris of the tumor tissue. After washing, the 
tissue was minced with forceps and a scalpel, and the 
blood vessels and apparent necrotic regions were removed. 
A trypsin solution (0.01%) (Gibco, Invitrogen) was added 
to the small pieces of tissue, followed by incubation at 37 ℃ 
for 30 minutes for the total digestion of the tissue to obtain 
a viable cell suspension. During this incubation, the minced 
sample was gently pipetted to aid cellular disaggregation. 
The viable cell suspension was then placed in a T25 flask 
containing DMEM (Dulbecco’s Modified Eagle Medium-
Sigma-Aldrich) supplemented with 10% FBS (Fetal 
Bovine Serum-Sigma-Aldrich) and 1% PS (Penicillin-
Streptomycin-Invitrogen) at 37 ℃  in a humidified 
atmosphere of 5% carbon dioxide in air. The medium 
was renewed every 48 or 72 hours, depending on the cell 
density and the growth kinetics. The primary cultures 
were considered established short-term culture when they 
reached ten passages. 
Immunocytochemistry
Approximately 1.0×106 cells were seeded on 15 mm circular 
coverslips and were incubated in DMEM supplemented with 
10% FBS and 1% PS at 37 ℃ in a humidified atmosphere 
of 5% carbon dioxide in air until they reached confluence. 
After that, the cells were fixed with 4% paraformaldehyde 
(Merck) and were permeabilized with 100% Triton-X 
(Merck). Immunocytochemistry was performed using the 
streptavidin-biotin-peroxidase complex system (UltraVision 
Large Volume Detection System Anti-Polyvalent, HRP; 
LabVision Corporation) according manufacturer’s 
instructions. Anti-GFAP (clone Z00334, DAKO) was used 
at a concentration of 1:1,000, and Anti-Nestin (clone 10C2, 
Novus Biologicals) was used at a concentration of 1:200. 
The chromogen DAB (3, 3’-Diaminobenzidine) was used to 
detect the immune reaction. The images were acquired by 
an Olympus Optical Microscope (magnification 100×).
DNA isolation 
For further molecular analysis, DNA was isolated from 
1.0×106 tumor cells in the third passage (3P) using TRIzol® 
(Life Technologies) according to the manufacturer’s 
instructions. For the frozen tumors, the tissue was 
macrodissected, ensuring more than 75% tumor cell 
content, and DNA (from tumor and blood) was isolated 
using a DNeasy Blood and Tissue Kit (Qiagen) following 
the manufacturer’s instructions. All of the DNA samples 
were quantified by a NanoDrop® 2000 (Thermo Scientific) 
and a Qubit® 2.0 Fluorometer (Life Technologies) and were 
then stored at −20 ℃ for genetic analysis.
Identification of the short tandem repeat (STR) profiles of 
the primary cultures 
The STR profiles were performed in the established short-
term primary cultures and were further compared with the 
corresponding patient blood DNA using a panel of eight 
STR loci (D5S818, D13S317, D7S820, D16S539, vWA, 
TH01, TPOX and CSF1P0) plus gender determination 
(AMEL), as previously reported (29,30) .
aCGH and data analysis
All four of the short-term primary cultures and respective 
frozen tumors were assessed by aCGH to evaluate the 
chromosomal alterations using the Agilent Human 
Genome CGH 8×60 K arrays following the manufacturer’s 
instructions (Agilent Technologies-version 7.1) as 
previously described by our group (31). The copy number 
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alterations (CNA) were evaluated by a comparison with the 
copy number found in the reference DNA (DNA universal 
control-Promega Madison WI USA-Male Reference: 
G147A; Woman Reference: G152A). 
The txt files generated by the Feature Extraction 
software, containing the intensity measurements for all of 
the spots were imported into a script written in R (32) for 
the bioinformatics analysis as previously described (31). The 
data were deposited under GEO Number GSE59967.
Ion Torrent sequencing and data analysis
The four short-term primary cell cultures and the frozen 
tumor tissues were sequenced using the Ion AmpliSeq™ 
Cancer Panel Primer Pool (Life Technologies), which 
analyzed the presence of mutations in 46 cancer related 
genes. The protocol was carried out according to the 
manufacturer’s instructions (Life TechnologiesTM) and as 
previously reported by our group (33). 
All of the analyses from the Ion Torrent sequencing were 
performed on the Torrent Server (Life TechnologiesTM). 
Sanger sequencing
The analysis of the hotspot mutations of TP53 (exons 5–8), 
BRAF (exon 15), IDH1 (exon 4), IDH2 (exon 4), FGFR1 
(exons 12 and 14), the TERT promoter region (hotspots 
-124 bp and -146 bp) and the PTEN gene (exons 1–9) was 
performed by PCR followed by direct sequencing. The 
primers and PCR conditions of TP53, BRAF, IDH1, IDH2, 
FGFR1, TERT and PTEN were previously described 
(34-39). 
The PCR products were then submitted to direct 
sequencing using an ABI PRISM BigDye Terminator Cycle 
Sequencing Ready Reaction Kit and were analyzed on a 
Genetic Analyzer ABI PRISM® 3500 (Applied Biosystems). 
The electropherograms were compared to GenBank (TP53: 
ENSG00000141510; PTEN: ENSG00000171862; BRAF: 
ENSG00000157764; IDH1: ENSG00000138413; IDH2: 
ENSG00000182054; H3F3A: ENSG00000163041; FGFR1: 
ENSG00000077782; TERT: ENSG00000164362). All of 
the samples that presented any alterations were confirmed 
with at least two additional independent amplifications and 
sequencing reactions.
Integration of chromosomal and mutation profiles
To perform the integration of chromosomal and mutation 
data and to assess the signaling pathway alterations, we 
input the CNA and mutations found in the Mondrian 
software plugin (http://cbio.mskcc.org/mondrian/) in the 
Cytoscape network visualization software (http://cytoscape.
org) using the data from one of the primary cultures as an 
example. 
Statistical analysis
The statistical analysis was performed using SPSS software 
(Statistical Package for Social Science version 19.0). The 
characterization of the Brazilian population in this study, 
including the clinico-pathological and molecular data, 
was performed using descriptive statistics (mean and 
frequencies). 
Results
Establishment, success rates and immunocytochemistry 
characterization of short-term glioblastoma primary 
cultures 
From February 2011 to December 2012, 67 primary glioma 
tumors were collected to obtain short-term primary cell 
cultures, and from these, 53.73% (36/67) successfully 
attached and grew. The cell lines were considered established 
short-term cultures when growing cultures attained at least 
10 passages without necessarily having been frozen and 
thawed. From the 36 established short-term glioblastoma 
primary cell cultures, the four with the most rapid and stable 
growth kinetics were characterized in more detail.
All four of the short-term glioblastoma primary cultures 
exhibited an attached, monolayer culture growth and 
showed a homogeneous morphology with a fibroblast-
like phenotype characteristic of glial cells (Figure 1A). 
The growth pattern or time until confluence of the short-
term primary cell cultures that reached the first passage 
(1P) varied between 7 to 10 days. Following this period, 
the attached and growing cells were passaged two more 
times and were characterized for GFAP expression. All of 
the cell lines showed strong GFAP expression (Figure 1B 
and Figure  S1A-C ) ,  and  in  accordance  wi th  the 
formalin-fixed paraffin-embedded primary tumors, 
GFAP immunostaining was analyzed in the Pathology 
department of Barretos Cancer Hospital for diagnostic 
purposes (data not shown). Similarly, all of the cell 
lines showed a predominantly strong Nestin expression 
(Figure 1C and Figure S1D-F).
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Clinico-pathological features of glioblastomas
The clinico-pathological features tumor localization, KPS, 
resection, patient status, and radio- and chemotherapy of 
the patients are summarized in Table 1. The mean age of 
the patients enrolled in this study was 57.75 years (ranging 
from 53 to 64) and the overall survival (OS) rate was 
5.75±3.4 months (mean ± SEM) (Table 1). The STR 
profile of the four short-term primary cell lines and the 
corresponding blood DNA confirmed that the short-term 
primary cell lines were derived from the corresponding 
patients (Table 2). 
aCGH profile
aCGH was performed in the four short-term primary cell 
cultures and the four corresponding frozen tumor tissues 
to evaluate the chromosomal abnormalities (Figure 2 and 
Figure S2). A summary of all of the DNA CNA detected 
in both the primary culture and the frozen tumor tissue 
is shown in Table 3. An overview of the CNA identified 
in the primary cell lines is represented in Figure 3. 
Amplifications were observed in the HCB144 cell line, 
and deletions were identified on the HCB29, HCB40 and 
HCB149 cell lines (Figure 2, Figure S2 and Table 3). In the 
HCB144 cell line, the amplified 4q11-q12 region harbored 
the PDGFRA, KIT and VEGFR2 oncogenes. The aCGH 
analysis showed that the most frequent events affected 
chromosomes 7, 10, 13, 17 and 19 (Figure 3). Gain of 
chromosome 7 was present in up to 80% of the cases, with a 
minimum gain region restricted to 7p12.1–q11.23, followed 
by gain of chromosome 19 (approximately 50%). Loss of 
chromosome 10 was found in all of the cases, and the region 
10p15.3–q26.3 was altered in all of the primary cell lines, 
followed by loss of chromosome 13 (approximately 60%) 
and loss of 17p (occurred in 40%) (Figure 3). The major 
CNAs were chromosomal losses with 82 events, followed 
by gains (79 events), and, less frequently, amplifications and 
deletions (Table 3). 
Figure 1 Representative image of the short-term glioblastoma primary culture and the GFAP and nestin proteins. (A) HCB29 primary 
culture (HCB29C) in DMEM +10% FBS +1% (PS, 40×); (B) immunocytochemistry of HCB29C showing GFAP expression, 100×; (C) 
immunocytochemistry of HCB29C showing nestin expression, 100×.
Table 1 Clinico-pathological features of the glioblastoma patients
ID Age (years) Gender Local KPS Resection Recurrence RT QT Status (July 2014) OS (months)
HCB29 53 F Left parietal 90 Partial No No No Death 3
HCB40 61 F Left temporal 50 Partial No No No Death 2
HCB144 64 F Left parietal 80 Total No No No Death 2
HCB149 53 F Left fronto-temporal 70 Total No Yes Yes Death 16
M, male; F, female; KPS, karnofsky performance status; RT, radiotherapy; QT, chemotherapy (temozolomide); OS, overall survival (months).
A B C
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Furthermore, the aCGH revealed that the 9p22.1–p21.3 
region was deleted in two of the cell lines (HCB29 and 
HCB149) and involved the MTAP, C9orf53 and CDKN2A 
genes (Table 3). In HCB40, we observed a deletion of the 
17q11 region, harboring the POLDIP2 gene (Table 3). 
When we compared the CNA profiles of the short-
term primary cell lines with the chromosomal alterations 
identified in the corresponding frozen glioblastoma 
tissues, the genomic profiles were very similar (Figure 2 
and Table 3). These findings were further corroborated 
by an unsupervised hierarchical cluster analysis, which 
showed close clustering of the paired primary culture and 
frozen tissue, with the exception of the HCB149 samples 
(Figure 4). Nevertheless, we also observed that some 
chromosomal aberrations were exclusively found in either 
the primary cell culture or the frozen tumor tissue (Table 3, 
Figure 2 and Figure 4).
Mutation profile
To determine the overall somatic mutational profiles in the 
glioblastoma study group, all of the short-term primary 
cell cultures and the frozen tumor DNA and blood DNA 
were sequenced initially performed using the Ion Torrent 
Figure 2 Genomeplot of a short-term primary culture (HCB29C) and the corresponding frozen tumor tissue (HCB29T). C, short-
term glioblastoma primary culture; T, frozen tumor tissue. The x-axis represents each of the chromosomes analyzed (excluding the Y 
chromosome), and the y-axis represents the log2 of the ratio of the intensity of the tumor DNA/control DNA. The green represents the 
chromosomal gain regions, and red represents the chromosomal loss regions.
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Table 2 Identification of the STR profile of the short-term primary cultures and the frozen tumor tissues
ID
STR
D5S818 D13S317 D7S820 D16S539 vWA TH01 TPOX CSF1PO AMEL
HCB29C 11; 13 12 7; 12 11 15 6; 8 6; 11 10; 11 X
HCB29B 11; 13 12 7; 12 11 15 6; 8 6; 11 10; 11 X
HCB40C 11 11; 13 8; 13 11; 12 18 7; 9.3 8 12 X
HCB40B 11 11; 13 8; 13 11; 12 18 7; 9.3 8 12 X
HCB144C 10; 11 9; 11 10; 13 9; 10 15; 17 7; 8 8; 11 10; 12 X
HCB144B 10; 11 9; 11 10; 13 9; 10 15; 17 7; 8 8; 11 10; 12 X
HCB149C 11; 12 13 12 11 15; 17 6; 9.3 8 11; 14 X
HCB149B 11; 12 13 12 11 15; 17 6; 9.3 8 11; 14 X
C, cell line primary culture; B, blood. 
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Table 3 Summary of copy number alterations of the short-term primary cultures and the frozen tumor tissues
ID
aCGH alterations
Gains Losses Amplifications Deletions
HCB29C 1q21.2–q23.3, 1q31.3–q32.1, 2p23.3–p22.3, 
2p16.1, 4q34.2–q34.3, 4q35.1, 5q23.2, 5q33.3, 
6q16.3–q21, 7, 8q12.1, 9p13.3, 9p22.2,  
12q12–q13.3, 15q22.31, 18q22.1, 19, 21q22.11, 
22q11–22–q13.31
1p36.33–p36.21, 1p36.12–p36.11, 
1p35.3, 1p33–p22.2, 2p12–p11.2, 
3p25.2––25.1, 3p25.1,  
3p14.3–p14.1, 4q32.1, 5p15–p13.3, 
5q11.2, 5q11.2–q14.1,  
8q23.2–q23.3, 9p24.3–p21.2, 
10p15.3–q26.3, 12q13.3–q14.1, 
13q12.11–q12.12, 13q21.33, 
14q11.2–q32.33, 17q24.2–q24.3, 
18q21.33–q22.1, 18q22.1, 19q13.33–
q13.41, 19q13.41–q13.43, 19
* 9p22.1–p21.3  
(MTAP, C9orf53, 
CDKN2A,  
CDKN2B)
HCB29T 1p36.21–p36.12, 1p36.11–p35.3, 1q32.1, 
2p23.2, 2p13.3–p13.1, 2p11.2, 2q35–q36.1, 
2q36.3–q37.3, 3p25.3, 3p25.1, 3p25.1, 3q21.3, 
3q27.2, 4p16.3–p16.1, 5p13.3, 5q11.2,  
5q32–q33.1, 6p21.33–p21.31, 6q27,  
7p22.3–p22.2, 7p15.1–p14.3, 7q11.22, 7q11.23, 
7q22.1, 7q32.1–q35, 7q36.1–q36.3, 8p23.1, 
8p21.3, 8q24.21, 8q24.3, 9p21.2, 9q33.3–q34.3, 
11p15.5–p15.4, 11q12.2–q13.4,  
12q13.11–q13.3, 13q34, 15q14, 16p13.3, 
16p11.2, 16q24.1–q24.2, 17p13.3–p13.1, 
17p11.2–q21.32, 17q24.3–q25.3, 18q23, 
19p13.3–p13.11, 19q13.13–q13.2,  
19q13.2–q13.33, 20q13.33, 22q13.1–q13.31, 
22q13.31–q13.33
1p36.33–p36.21, 1p36.12–p36.11, 
1p35.3, 1p33–p22.2, 1p12–q21.1, 
3p25.3–p25.1, 3p25.1,  
3p14.3–p14.1, 5q11.2–q14.1, 
9p24.3–p21.2, 10p15.3–q26.3, 
13q11–q12.12, 13q21.33,  
14q11.2–q23.2, 14q23.2–q32.32, 
14q32.33, 15q11.1–q11.2,  
18q21.1–q21.2, 19p13.11–q13.11, 
19q13.2, 19q13.33–q13.43, 22q13.31
* *
HCB40C 1p36.31–p36.22, 1p36.22–p36.12, 1p35.3–
p31.3, 1p31.1–p21.2, 1p13.3–q25.3, 2p16.1, 
3p13, 3q26.2–q29, 4q34.2–q34.3, 5q23.2, 5q32, 
5q33.1, 5q33.3, 6q13, 6q16.3–q21, 7, 11p15.4, 
12q24.23, 13q11–q12.12, 13q21.33–q22.3, 
13q31.3–q32.3, 14q11.2, 14q21.2–q32.33, 
14q32.33, 15q11.2–q13.1, 15q13.3–q22.31, 
17q23.3–q25.3, 18q22.1, 20p13–q13.33, 
21q21.3–q22.13
1p36.22, 1p36.12–p35.3, 1q44, 
2p25.3–p23.3, 2p12–p11.2,  
2q22.1–q32.3, 3p26.3,  
4q34.1–q34.2, 4q34.3–q35.1, 
4q35.1–q35.2, 5q23.2–q23.3, 
9p24.3–p23, 9q33.3, 9q34.13–q34.3, 
10p15.3–q26.3, 11q13.4–q23.3, 
12q15–q21.33, 13q12.12–q21.1, 
15q11.1–q11.2, 15q13.2, 16q12.1, 
17p13.3–q21.1, 17q21.2–q23.3, 
17q25.3, 18q21.33–q22.1, 18q22.1, 
19p13.2
* 17q11.2 
(POLDIP2)
HCB40T 1p36.33–p36.12, 1p35.3–p31.3, 1q21.1–q23.2, 
1q32.1, 2p23.3–p23.2, 2p11.2, 2q34, 3p26.3, 
3q21.2–q22.1, 5p13.3, 7p22.3–p21.3,  
7p21.3–q35, 7q35–q36.3, 8p23.1, 8p21.3, 
8p11.23, 8q24.21, 8q24.3, 9q33.3–q34.11, 
11q23.3, 12q13.13, 12q24.23, 15q13.3, 
15q14, 16p13.3, 16p12.1–p11.2, 16q21–q22.1, 
17q25.1–q25.3, 17q25.3, 19p13.3–p13.2, 
19p13.2–p13.11, 19p12–q13.43, 20p12.1, 
20q13.33, 21q22.11, 21q22.3, 22q11.1–q13.33, 
23p22.2–p22.12
1p12–q21.1, 1q44, 2q34,  
2q34–q35, 2q37.3, 3p26.3,  
8p11.22–p11.21, 10p15.3–q22.1, 
11p15.4, 11q22.3–q23.1, 11q23.3, 
12q13.13, 12q24.31–q24.33, 
13q12.13–q21.1, 15q11.1–q11.2, 
15q13.1–q13.3, 17p13.1–p11.2, 
17q11.2–q12, 17q21.31–q23.3, 
19p13.2
* *
Table 3 (continued)
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Table 3 (continued)
ID
aCGH alterations
Gains Losses Amplifications Deletions
HCB144C 1p36.31–p33, 1p13.3–q31.1, 1q31.3–q44, 
2p16.1, 3p23–p14.3, 3p13, 4q11–q12, 4q35.1, 
5q33.3, 6, 7p12.1–q11.23, 8p22, 8q12.1, 
9p24.3–q34.3, 11q12.3, 14q11.2, 14q24.3, 
17q21.1–q21.2, 19p13.3–q13.43, 22q11.22, 
23p22.33–q28
3q11.2–q13.13, 4p16.3–p14,  
4p14–q11, 4q12–q35.1, 4q35.2, 
5p15.33–p15.2, 5p15.1–p13.3, 
8q23.1–q23.3, 10p15.3–q26.3, 
11p14.1–p13, 11p13–q12.3, 
11q12.3–q23.3, 11q23.3–q25, 
12p13.33–q12, 12q13.2–q24.33, 
13q11–q34, 17p13.2–p13.1, 18q22.1, 
19q13.43, 21p11.1–q21.3,  
21q22.12–q22.3
4q11–q12  
(PDGFRA, 
KIT, VEGFR2), 
19q13.11–
q13.12
*
HCB144T 1q21.1–q22, 1q23.1–q23.2, 1q32.1, 2q33.1, 
3p25.3–p25.1, 3p22.1–p14.2, 3q27.2, 3q29, 
4q11–q12, 6p25.3–q22.32, 6q22.33–q27, 7p13, 
7p12.1–q11.23, 7q22.1, 9p24.3–q34.3, 11p13, 
11p11.12, 11q11–q12.1, 15q14, 16p12.1–
p11.2, 17p13.3–p13.2, 17q12, 17q24.3–q25.3, 
19p13.3–q13.33, 19q13.33–q13.42, 19q13.43, 
20p13, 23p22.33–q28
1p31.1–p22.3, 1q25.3–q31.3, 
2p25.3–p25.1, 2p13.1–p11.2, 
3q11.2–q13.13, 4p16.1–p11,  
4q13.1–q13.3, 4q22.1–q35.1, 4q35.2, 
7q21.11, 7q22.3–q31.33,  
8p11.22–p11.21, 8q23.1–q23.3, 
10q11.23–q21.3, 11p14.3–p13, 
11p11.2–q11, 12p13.33–p12.3, 
12q12, 12q13.13, 12q13.3–q21.33, 
12q23.3, 12q24.31–q24.33,  
13q11–q34, 15q11.1–q14,  
15q14–q22.2, 15q26.1–q26.3, 
17p13.2–p13.1, 19q13.43,  
20q11.23–q12, 21p11.1–q22.11
4q11–q12  
(PDGFRA, 
KIT, VEFGR2), 
19q13.11–
q13.12
*
HCB149C 1q21.1–q23.3, 1q31.3–q42.12, 5q32, 5q33.1, 
5q33.3, 7, 12q13.13, 14q32.33, 21q22.11
6p12.3–p11.1, 8p23.3–p21.1,  
8p12–q12.1, 9p24.3–p21.1,  
10p15.3–q26.3, 13q11.q34,  
14q11.2–q12, 16p13.13–p11.2, 
17p13.3–p12, 21q22.13,  
22q11.22–q13.33
* 9p22.1–p21.3  
(MTAP, C9orf53, 
CDKN2A)
HCB149T 1p36.33–p34.1, 1p22.1, 1q21.1–q22,  
1q23.1–q23.2, 2p11.2, 3q21.3, 3q22.1, 3q27.2, 
5q32–q33.1, 5, q35.3, 6p21.1, 7p22.3–q11.23, 
7q21.3–q22.1, 7q32.1–q36.3, 8p11.23–p11.22,  
8q11.21, 8q11.21, 8q24.3, 9q33.3–q34.3, 
11q15.5, 11p15.4, 11p11.2, 11q12.2–q13.4, 
12q13.11–q13.2, 12q24.33, 13q12.13, 14q32.33, 
15q14, 15q23–q24.1, 16p13.3, 16p11.2, 
16q12.2–q13, 16 q21–q22.1, 17q12,  
17q12–q21.32 , 17q24.3–q25.3,  
19p13.3–p13.11, 19 q13.12–q13.2,  
19q13.2–q13.33, 19q13.33–q13.43, 19, 
20q13.33, 23p22.33–q28
1p22.1–p21.3, 1p12–q21.1,  
6p12.3–p11.2, 8p23.3–p11.23, 
8p11.22–p11.21, 8p11.21,  
9p24.3–p21.2, 10p15.3–q24.31, 
10q24.33–q26.3, 13q11–q12.13, 
13q12.13–q34, 14q11.2,  
14q11.2–q12, 17p13.1–p12, 
19p13.11–q13.11, 19q13.33, 
22q13.31–q13.32
8p11.23–p11.22 *
*, no amplification or deletion. p, short chromosome arm; q, long chromosome arm. 
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platform. We observed oncogenic mutations in the BRAF, 
RB1 and TP53 genes, as shown in Table 4. To validate the 
mutation status identified by Ion Torrent in a subset of 
genes (TP53, BRAF, FGFR1, IDH1, IDH2 and PTEN) and 
to extend to other important genes (TERT promoter region) 
not included in the AmpliSeq panel, we performed Sanger 
sequencing of the hotspot regions of those genes (Table 4). 
With the exception of the PTEN mutation (p.Gly165Glu), 
both Sanger and Ion Torrent identified the same alterations. 
This PTEN mutation was in a codon that was not covered 
by the AmpliSeq library. The most frequently mutated gene 
was the TERT promoter, which was found in 3 of the 4 
short-term primary cell lines, followed by TP53 mutations 
in 2 of the 4 short-term primary cultures. Additionally, we 
found mutations in the BRAF and RB1 genes. No mutations 
were detected in the IDH1, IDH2, and FGFR1 genes.
As shown in Table 4, all of the mutations observed in 
the short-term primary cell lines, except for PTEN, as 
shown above, were also found in the frozen tumor tissues, 
confirming that the cell culture environment did not lead to 
acquisition of additional somatic mutations. 
 
Discussion
To gain a better understanding of the biology of 
glioblastoma and to contribute to future functional and 
therapeutic studies, we obtained short-term glioblastoma 
primary cultures and characterized their chromosomal and 
molecular alterations. We showed that the four short-term 
glioblastoma cell cultures harbored a genomic profile that 
was similar to the corresponding matched frozen tumors, 
suggesting that they might constitute a reliable model for 
more detailed preclinical studies. 
The success rate in the establishment of the short-term 
primary cell tumors varies greatly among studies (40-42). 
Several methodologies have been used for the establishment 
of primary glioma cell lines (26,40). Some authors use 
growth factors, such as bFGF and EGF, without serum, 
whereas others used serum-cultured conditions (41,42). The 
presence of serum in the culture is described to induce the 
differentiation and expansion of neoplastic cells, potentially 
eliminating the glioma stem cells (41-43). Lee et al. 
reported that glioblastoma primary cell lines grown without 
serum have the capability to form neurospheres in vitro, 
have a vast potential to self-renew, undergo multilineage 
differentiation, have genetic stability over serial passages and 
harbor all of the alterations found within primary tumors, 
while the same cells cultured under serum conditions lose 
these abilities and change their gene expression profiles (42). 
Similarly, Behnan et al. studied glioblastoma primary 
cultures under different conditions, such as neurospheres 
and adherent cell lines without and with serum (43). They 
observed that glioblastoma cell lines in serum conditions 
lose their tumorigenicity potential after the removal the 
Figure 3 Frequency of the gains and losses in the four short-term glioblastoma primary cultures. The x-axis represents each of the 
chromosomes analyzed (excluding the Y chromosome), and the y-axis represents the frequency of the gains and losses. The green bars 
represent the chromosome gains, and the red bars show the chromosome losses.
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non-adherent cells, but when grown in a mixed condition, 
they express both phenotypes, tumorigenic and non-
tumorigenic profiles, suggesting that the serum does not 
preclude the glioblastoma cells’ tumorigenicity since the 
cell culture condition allows the growth of the tumorigenic 
cells (43). We and others used serum-containing medium, 
and the subsequent molecular analysis showed that short-
term primary cultures exhibited a profile that was similar 
to their tumor tissue counterparts (27,28,40). Therefore, 
despite this putative limitation in tumor cell culture that 
is not enriched for the heterogeneity of tumor cell type of 
glioblastomas, we observed identical genetic alterations.
The copy number analysis of all four of the glioblastoma 
cell lines showed that the most prevalent alterations affected 
chromosomes 7, 10, 13, 17 and 19, confirming previous 
studies in glioblastoma, including those from our group 
(13,31,44,45). Brennan et al. (17) and Beroukhim et al. (20) 
observed that chromosomal losses were more frequent than 
amplifications, as shown in this study. The amplification 
of the important region 4q12, which harbors the KIT, 
PDGFRA and KDR oncogenes, was observed in one case. 
This finding is in agreement with other studies that showed 
a portion of adult glioblastomas with co-amplification 
of these genes (17,22,28,46-48). It is important to note 
that PDGFRA amplification is more common in pediatric 
glioblastoma or diffuse intrinsic pontine gliomas (DIPG) 
than in adult glioblastoma (22,31). The deletion of the 
region 9p22.1–21.3, involving the CDKN2A/B, MTAP and 
C9orf53 genes, was seen in half of the established short-
term cell lines, which is in accordance with previous studies 
(12,17,45,49). Importantly, the tumor suppressor gene 
CDKN2 is involved in the development of glioblastoma, 
with a high-level homozygous deletion (12,17). This finding 
also corroborates the integrated analysis of TCGA that 
showed that the RB pathway is one of the most altered 
in gliomagenesis (14,17). TCGA_2008 (14) showed that 
an integrated analysis of the complex chromosomal and 
genetic aberrations in glioblastoma provides an overall 
evaluation of the biology of glioblastoma and points toward 
potential therapeutic strategies. Using a similar approach, 
we observed that most of the alterations occur in these 
three signaling pathways, including the RTKs and p53 
and RB, in concordance with TCGA data (Figure S3). 
Although the importance of MTAP in gliomas has not 
been well studied, this deletion has been reported with 
high frequency in glioblastoma (39,50,51). Another deleted 
region was 17q11.2, which is composed of the POLDIP 
2 gene, or POLD2. The role of the POLDIP 2 gene in 
glioblastoma is very poorly characterized, with just a study 
suggesting the association with survival patients (52). 
However, we could not dispute its importance, since it 
is related to DNA replication and repair, besides being 
regulated by PTEN (52). Furthermore, the comparison of 
the CNA profiles of the short-term primary cell lines with 
respective frozen tumor tissues showed that they clustered 
together, with concordant chromosomal copy number 
profiles. The unique short-term culture and the frozen 
tumor tissue that did not cluster together was HCB149. 
Nevertheless, minor alterations found uniquely either in 
short-term primary cell culture or in frozen tumor tissue 
were detected. Such small discrepancies between the frozen 
and cultured tumors can be justified by the enrichment of 
Figure 4 Unsupervised hierarchical clustering analysis of the 
short-term primary cell cultures and the frozen tumor tissues. 
The x-axis represents the chromosomes evaluated. The y-axis 
corresponds to the frozen tumor samples. C, primary culture; T, 
primary tumor. Amp, amplification; Del, deletion.
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the tumor cells in the cell culture environment and have 
also been reported by other studies (21,40). 
The evaluation of the mutation profile using the 
AmpliSeq panel (IonTorrent platform) showed the 
presence of oncogenic mutations on the BRAF, RB1 
and TP53 genes. The RB1 gene mutations are reported 
to be highly frequent in primary glioblastoma (13); 
however, we could not observe this high frequency in the 
analyzed samples, which was probably due to our small 
sample size. The findings of the TP53 (2/4) and BRAF 
(1/4) genes, although not the most expected in primary 
glioblastomas, are in concordance with some studies also 
reporting the presence of these alterations in primary 
glioblastoma (14,53). However, it is important to highlight 
that TP53 and BRAF gene mutations are more frequent 
in secondary (12,54) and pediatric glioblastomas (18). 
To validate these results, we performed Sanger sequencing 
of select mutated genes and evaluated the additional 
mutation status of the hotspot in the TERT promoter 
region, which has been reported as a major player in the 
development of glioblastoma (50,55). As expected, we found 
a high frequency (75%) of this hotspot TERT promoter 
mutation (c.-124C > T), in concordance with recent studies 
(23,24,56). TERT promoter mutations have been extensively 
associated with malignant development, including 
glioblastoma, due to its capacity to induce telomerase 
Table 4 Mutation profile of the short-term primary cell cultures and the corresponding frozen tumor tissues
ID Platform Chrom Gene Exon Codon Mutation AA chance Mutations type
HCB29C Ion Torrent 7 BRAF 15 600 GTG → GAG Val → Glu Missense
Sanger 7 BRAF 15 600 GTG → GAG Val → Glu Missense
HCB29T Ion Torrent 7 BRAF 15 600 GTG → GAG Val → Glu Missense
Sanger 7 BRAF 15 600 GTG → GAG Val → Glu Missense
HCB40C Ion Torrent 13 RB1 17 552 CGA → TGA Arg → Stop Nonsense
17 TP53 8 273 CGT → CAT Arg → His Missense
Sanger 5 TERT – – G>A –124bp –
17 TP53 8 273 CGT → CAT Arg → His Missense
HCB40T Ion Torrent 13 RB1 17 552 CGA → TGA Arg → Stop Nonsense
17 TP53 8 273 CGT → CAT Arg → His Missense
Sanger 5 TERT – – G>A –124bp –
17 TP53 8 273 CGT → CAT Arg → His Missense
HCB144C Ion Torrent 7 TP53 6 216 GTG → ATG Val → Met Missense
Sanger 5 TERT – – G>A –124bp –
10 PTEN 6 165 GGA → GAA Gly → Glu Missense
17 TP53 6 216 GTG → ATG Val → Met Missense
HCB144T Ion Torrent 7 TP53 6 216 GTG → ATG Val → Met Missense
Sanger 5 TERT – – G>A –124bp –
10 PTEN 6 165 GGA → GAA Gly → Glu Missense
17 TP53 6 216 GTG → ATG Val → Met Missense
HCB149C Sanger 5 TERT – – G>A –124bp –
HCB149T Sanger 5 TERT – – G>A –124bp –
Chrom, chromosome; C, primary culture; T, primary tumor; bp, base pairs. A, adenine; C, cytosine; G, guanine, T, thymine. Gly, glycine; 
Val, valine; Glu, glutamic acid; Arg, arginine; Stop, stop codon; His, histidine; Met, methionine.
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reactivation (57,58). 
As expected, no mutations were seen in the IDH1 and IDH2 
genes, which is common in secondary glioblastomas (59), 
and none were seen in FGFR1, which is frequent in 
pediatric tumors (25). All of the mutations were identified 
in both the short-term primary cell cultures and the 
frozen tumor tissues, indicating that the alterations were 
not induced by the cell culture environment.
Conclusions
In conclusion, the present findings showed the successful 
establishment of short-term glioblastoma primary cultures, 
which exhibited chromosomal and genetic alterations 
in regions previously associated with glioblastoma 
tumorigenesis. Moreover, these glioblastoma cultures 
demonstrated good reproducibility and concordance 
between the genomic profiles of the short-term primary cell 
cultures and the respective frozen tumor tissues, indicating 
their utility for preclinical studies of glioblastoma biology. 
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Supplementary
Figure S1 Representative image of the GFAP and Nestin proteins in the short-term glioblastoma primary culture. (A-C) 
Immunocytochemistry of the GFAP expression of HCB40, HCB144 and HCB149 (100×); (D-F) immunocytochemistry of the Nestin 
expression of HCB40, HCB144 and HCB149 (100×).
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Figure S2 Genomeplot of the short-term primary cultures (HCB40C, HCB144C and HCB149C) and the corresponding frozen tumor 
tissues (HCB40T, HCB144T and HCB149T). C, short-term glioblastoma primary culture; T, frozen tumor tissue. The x-axis represents 
each of the chromosomes analyzed (excluding the Y chromosome), and the y-axis represents the log2 of the ratio of the intensity of the 
tumor DNA/control DNA. The green represents the chromosomal gain regions, and red represent the chromosomal loss regions.
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Figure S3 Signaling pathway alterations in the HCB144 primary culture. As in the TCGA study, the signaling pathway alterations were 
based on CNA and mutations. The CNA is represented by both circles representing proteins as rectangles below. The rectangles show CNA 
data on the left, and the gene mutation is on the right. Light red shows the chromosomal gains, and light blue represents chromosomal 
losses, while dark red indicates amplification and yellow represents mutation. The white rectangles represent genes without a CNA or 
a mutation, and the gray rectangles indicate that there was no information. TCGA, The Cancer Genome Atlas; CNA, copy number 
alterations.
